Cost-effectiveness
Treatment costs in the SAP group were €1030 (95 per cent c.i., 885 to 1092) per patient including the cost of additional DUS, and €1660 (1544 to 1779) in the TAP group, The SAP treatment was on average €630 (571 to 782) less costly than the TAP treatment.
Cost-effectiveness planes for VEINES-QOL (a) and VEINES-Sym (b).VEINES-QOL/Sym, VEnous INsufficiency Epidemiological and Economic Study Quality of Life/Symptoms; SAP, isolated ambulatory phlebectomy with or without delayed endovenous truncal ablation; TAP, thermal ablation with concomitant phlebectomy.